These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 12630645)

  • 1. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
    Tanwani LK; Mokshagundam SL
    South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic alterations in HIV-associated lipodystrophy syndrome].
    Valente AM; Reis AF; Machado DM; Succi RC; Chacra AR
    Arq Bras Endocrinol Metabol; 2005 Dec; 49(6):871-81. PubMed ID: 16544008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.
    Chen D; Misra A; Garg A
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic complications in HIV infection. In search of underlying mechanisms.
    Johnson DL
    Adv Nurse Pract; 2002 Jul; 10(7):45-50, 76. PubMed ID: 12420551
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies.
    Koutkia P; Grinspoon S
    Annu Rev Med; 2004; 55():303-17. PubMed ID: 14746523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection.
    Norris A; Dreher HM
    J Assoc Nurses AIDS Care; 2004; 15(6):46-64. PubMed ID: 15538016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
    Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
    Hadigan C; Meigs JB; Corcoran C; Rietschel P; Piecuch S; Basgoz N; Davis B; Sax P; Stanley T; Wilson PW; D'Agostino RB; Grinspoon S
    Clin Infect Dis; 2001 Jan; 32(1):130-9. PubMed ID: 11118392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
    Dubé MP
    Clin Infect Dis; 2000 Dec; 31(6):1467-75. PubMed ID: 11096014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
    Grinspoon SK
    Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.